ACRS logo

Aclaris Therapeutics, Inc.

ACRS

ACRS: Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

more

Show ACRS Financials

Chart and Financial Data provided by TradingView

All
Government
Consumer Interest
SEC Filings
ESG/Other
Congress Trading

Recent trades of ACRS by members of U.S. Congress

Quiver Logo

No Congress Trading data for this ticker

Congress Trading Dashboard
Whale Activity

Recently reported changes by institutional investors

Insider Trading

Quarterly net insider trading by ACRS's directors and management

Corporate Lobbying

Government lobbying spending instances

Quiver Logo

No Corporate Lobbying instances for this ticker

Corporate Lobbying Dashboard
U.S. Patents

New patents grants

  • Patent Title: Substituted pyrrolopyridine jak inhibitors and methods of making and using the same Aug. 29, 2023
  • Patent Title: Substituted pyrrolopyridine jak inhibitors and methods of making and using the same Apr. 20, 2021
  • Patent Title: Pyrazolyl pyrrolo[2,3-b]pyrmidine-5-carboxylate analogs and methods of making the same Oct. 13, 2020
  • Patent Title: Peroxide formulations and methods and applicators for using the same Aug. 04, 2020
  • Patent Title: Peroxide formulations and methods and applicators for using the same May. 19, 2020
  • Patent Title: Peroxide formulations and methods and applicators for using the same Dec. 03, 2019
  • Patent Title: Stabilized oxymetazoline formulations and their uses Jul. 02, 2019
  • Patent Title: Pyrrolopyrimidine itk inhibitors for treating inflammation and cancer Jun. 11, 2019
  • Patent Title: Heterocyclic itk inhibitors for treating inflammation and cancer Dec. 11, 2018
  • Patent Title: Peroxide formulations and methods and applicators for using the same Oct. 16, 2018
  • Patent Title: Peroxide formulations and methods and applicators for using the same May. 29, 2018
  • Patent Title: Peroxide formulations and methods and applicators for using the same Jun. 13, 2017
Government Contracts

Federal grants, loans, and purchases

Quiver Logo

No Government Contracts for this ticker

Government Contracts Dashboard
WallStreetBets

Number of mentions of ACRS in WallStreetBets Daily Discussion

ACRS News

Recent insights relating to ACRS

CNBC Recommendations

Recent picks made for ACRS stock on CNBC

Top ETF Holders

ETFs with the largest estimated holdings in ACRS

Corporate Flights

Flights by private jets registered to ACRS